{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=19", "query": { "condition": "Phase III", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 10486, "total_pages": 1049, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T22:34:30.248Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00254384", "title": "Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage IA Lung Non-Small Cell Carcinoma AJCC v7", "Stage IB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2005-10-05", "completion_date": "2024-05-21", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00254384" }, { "nct_id": "NCT00496158", "title": "Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis", "Hepatitis B" ], "interventions": [ { "name": "Clevudine", "type": "DRUG" }, { "name": "Adefovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmasset", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2007-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-04-27", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Anaheim, California • Fresno, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00496158" }, { "nct_id": "NCT02487108", "title": "Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "TV-46763", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 569, "start_date": "2015-08-11", "completion_date": "2016-03-30", "has_results": true, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Anaheim, California • Bakersfield, California + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Pasadena", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02487108" }, { "nct_id": "NCT06493552", "title": "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "SEphB4-HSA", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vasgene Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2025-03-15", "completion_date": "2034-08", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06493552" }, { "nct_id": "NCT00080925", "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2004-02", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080925" }, { "nct_id": "NCT01231906", "title": "Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Localized Extraskeletal Ewing Sarcoma", "Peripheral Primitive Neuroectodermal Tumor of Bone", "Peripheral Primitive Neuroectodermal Tumor of Soft Tissues" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": 642, "start_date": "2010-11-24", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 215, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231906" }, { "nct_id": "NCT03893448", "title": "Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections", "Pneumococcal Vaccines" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "RotaTeq™", "type": "BIOLOGICAL" }, { "name": "Pentacel™", "type": "BIOLOGICAL" }, { "name": "RECOMBIVAX HB™", "type": "BIOLOGICAL" }, { "name": "VAQTA™", "type": "BIOLOGICAL" }, { "name": "MMR II™", "type": "BIOLOGICAL" }, { "name": "VARIVAX™", "type": "BIOLOGICAL" }, { "name": "HIBERIX™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "90 Days", "sex": "ALL", "summary": "42 Days to 90 Days" }, "enrollment_count": 1720, "start_date": "2019-06-19", "completion_date": "2021-05-24", "has_results": true, "last_update_posted_date": "2023-07-28", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Opp", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893448" }, { "nct_id": "NCT02752035", "title": "A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation" ], "interventions": [ { "name": "gilteritinib", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2016-08-01", "completion_date": "2024-12-18", "has_results": true, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 12, "location_summary": "Los Angeles, California • Orange, California • Chicago, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02752035" }, { "nct_id": "NCT00906308", "title": "A Study of MF101 in Postmenopausal Women", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hot Flushes", "Vasomotor Symptoms" ], "interventions": [ { "name": "MF101 5 g/day", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "MF101 10 g/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bionovo", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "40 Years to 65 Years · Female only" }, "enrollment_count": 1200, "start_date": "2011-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-02-08", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 44 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00906308" }, { "nct_id": "NCT06585787", "title": "A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "KarXT", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 406, "start_date": "2024-09-26", "completion_date": "2026-12-22", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-29T22:34:30.248Z", "location_count": 102, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 71 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06585787" } ] }